Myxobacterial secondary metabolites: bioactivities and modes-of-action

Covering: up to 2010 The myxobacteria, long a source of fascination due to their sophisticated, social lifestyles, are now increasingly recognized as multi-producers of promising natural products. Here we provide an overview of the bioactivities and modes-of-action of these secondary metabolites, wi...

Full description

Saved in:
Bibliographic Details
Published inNatural product reports Vol. 27; no. 9; pp. 1276 - 1295
Main Authors Weissman, Kira J, Müller, Rolf
Format Journal Article
LanguageEnglish
Published England 01.09.2010
Subjects
Enzymes - biosynthesis
Myxococcales - enzymology
Myxococcales - metabolism
Online AccessGet full text

Cover

More Information
Summary:Covering: up to 2010 The myxobacteria, long a source of fascination due to their sophisticated, social lifestyles, are now increasingly recognized as multi-producers of promising natural products. Here we provide an overview of the bioactivities and modes-of-action of these secondary metabolites, with an emphasis on potential clinical applications. This review provides a comprehensive overview of the bioactivities and modes-of-action of secondary metabolites derived from the myxobacteria, highlighting their therapeutic potential.
Bibliography:Kira J. Weissman obtained her BS in Chemistry from Stanford University, California, in 1995. Receipt of a Churchill Fellowship allowed her to relocate to the United Kingdom, where she carried out MPhil (1996), PhD (2000) and post-doctoral research at the University of Cambridge with Professors Jim Staunton and Peter Leadlay. Her work at Cambridge was supported by several fellowships, including a Royal Society Dorothy Hodgkin Fellowship. She is presently a Senior Scientist at the University of Saarland, Saarbrücken, Germany, working with Prof. Rolf Müller. Kira's research interests include the mechanistic enzymology and structural biology of modular PKS and NRPS systems.
Rolf Müller studied pharmacy in Bonn and received his PhD in 1994 with Eckhard Leistner. After postdoctoral work with Heinz Floss he moved to the German Research Center for Biotechnology in Braunschweig as a junior research group leader. The group moved to Saarland University in 2003 (Chair of Pharmaceutical Biotechnology). In 2006, Rolf also assumed a position at the Helmholtz Center for Infection Research (HZI) in Braunschweig. In 2009, Saarland University and HZI founded the Helmholtz Institute for Pharmaceutical Research Saarland, where Rolf now serves as founding director. He coordinates efforts to develop an integrated and multi-disciplinary approach to studying myxobacteria.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0265-0568
1460-4752
DOI:10.1039/c001260m